Ying Cheng

50PUBLICATIONS

285CO-AUTHORS

Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsGene and molecular therapyTumour immunology

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (50)

Sort by Publication Date:

|Sep 27, 2026

Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3 results from the RC48-C006 phase 2/3 trial.

|Mar 14, 2026

Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.

Yang Sun, Hongying Yang, Jing Wang

|Dec 18, 2025

Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial.

Yongmei Yin, Qingyuan Zhang, Tao Sun

|Nov 03, 2025

Oncogenic KRAS mutations drive immune suppression through immune-related regulatory network and metabolic reprogramming.

Lin Tian, Hui Li, Heran Cui

|Oct 07, 2025

IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer.

Taofeek K Owonikoko, Lauren Byers, Ying Cheng

|Aug 19, 2025

First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial.

Shaodong Hong, Qiming Wang, Ying Cheng

Pageof 9

Frequent Collaborators

Lin Wu

Yi-Long Wu

Suresh S Ramalingam

Byoung Chul Cho

Hong-Hong Yan

Shun Lu

Jhanelle E Gray

Ryan J Hartmaier

Qiming Wang

Jie Wang

Frequent Collaborators

Lin Wu

Yi-Long Wu

Suresh S Ramalingam

Byoung Chul Cho